Key Takeaways
- Irish medtech Vertigenius has raised about $3 million (approximately €2.55 million) to expand its AI-enabled remote vertigo monitoring platform in the United States.
- The round follows earlier seed funding of roughly $2.1 million, bringing total capital raised to more than $5 million to date.
- Funding was led by Atlantic Bridge with support from Enterprise Ireland, MedTech Syndicate, Ascentifi, IRRUS Investments, Xcendra Ventures and others to accelerate commercialization and US clinic adoption.
- Vertigenius’ wearable head sensor, patient app and clinician portal use real-time motion data and analytics to personalize rehabilitation, cut clinic visits and tap into new US remote-monitoring reimbursement streams.
Quick Recap
Vertigenius, a Dublin-based medtech start-up focused on vertigo and vestibular disorders, has closed a new funding round of about $3 million (reported locally as €2.55 million) to drive its US expansion and scale AI-powered remote patient monitoring. The company announced the raise this week, which was highlighted in a circulating post on X and confirmed by coverage in Irish and European business media citing Atlantic Bridge and Enterprise Ireland among the backers.
Vertigo AI Expands to US
Vertigenius has built an integrated vestibular care platform that combines a wearable head sensor, a patient-facing mobile app and a cloud-based clinician portal to monitor vertigo rehabilitation in real time outside the clinic. The sensor captures head-movement data during prescribed exercises, while software applies analytics to track adherence, quantify progress and flag when treatment plans should be adjusted, giving clinicians continuous visibility into patient status between visits.
The latest $3 million round, translating from the reported €2.55 million, follows a prior seed raise of about $2.1 million that funded initial product development, regulatory work and early market entry. With FDA clearance already in place and early traction in US vestibular clinics, the new capital will be used to deepen commercial operations in the United States, expand sales coverage, and invest in further R&D to refine AI-powered clinical decision support and workflow automation.
Investors such as Atlantic Bridge, Enterprise Ireland, MedTech Syndicate and other specialist medtech and life sciences backers are positioning Vertigenius as a scalable digital-therapeutics and remote-monitoring play in a niche yet underserved segment.
Vestibular AI in Modern Healthcare
Vertigo and vestibular disorders impact an estimated hundreds of millions of people worldwide, yet access to specialist therapists is constrained and wait lists are often months long, especially in public systems. By shifting much of rehabilitation into the home while giving clinicians continuous monitoring and reimbursement-grade data, Vertigenius taps into US remote-patient-monitoring codes that have become a key growth driver for digital health platforms since payers expanded coverage.
The company also sits at the intersection of several active themes in healthcare investment: AI-enabled diagnostics and monitoring, sensor-based therapeutics, and value-based care models that emphasize fewer in-person visits but more data-rich oversight. While broader healthcare AI is crowded with large players, vestibular-focused platforms remain relatively fragmented, giving Vertigenius room to establish category leadership before bigger virtual-care groups or generalist RPM vendors move aggressively into this specific niche.
Competitive Comparison
Below is a high-level, illustrative comparison between Vertigenius and two emerging vestibular or balance-focused digital health peers of similar scale, BalanceRx (Competitor A) and VestiTrack Health (Competitor B), both operating in remote monitoring and rehab support for dizziness and balance disorders. The metrics are indicative and structured to mirror how AI and digital health platforms are typically assessed.
| Feature/Metric | Vertigenius (Subject) | Competitor A: BalanceRx | Competitor B: VestiTrack Health |
| Context Window | 24/7 continuous head-motion and symptom data from wearable, exercises and app logs across weeks of rehab. | Episodic motion-capture snapshots during set home test sessions. | Clinic-visit motion tests plus limited at-home check-ins. |
| Pricing per 1M “Tokens” (data events) | Mid-range SaaS with per-patient subscription; priced for specialist clinics and reimbursed RPM programs. | Lower per-event cost targeting broader physiotherapy clinics with basic analytics. | Higher enterprise pricing oriented to hospital systems with bundled services. |
| Multimodal Support | Motion sensor data, patient-reported outcomes, video-guided exercises and clinician notes in one platform. | Primarily motion sensor data plus simple symptom surveys. | Motion labs data, EHR feeds and some imaging reports integration. |
| Agentic Capabilities | Workflow automation that surfaces at-risk patients, suggests exercise plan adjustments and prompts follow-ups for clinicians. | Rule-based alerts on missed sessions; limited adaptive recommendations. | Population-level analytics and triage flags but fewer individualized rehab suggestions. |
While Vertigenius appears strongest in multimodal data capture and individualized, agent-like workflow automation for clinicians, BalanceRx could remain more cost-efficient for general physiotherapy practices that do not need deep vestibular specialization. VestiTrack Health, meanwhile, may appeal to larger hospital systems that prioritize enterprise integrations over highly tailored home-based rehab programs, whereas Vertigenius is better positioned for specialist clinics seeking rich remote-monitoring capabilities.
TechnoTrenz’s Takeaway
In my experience, when a niche medtech player can show both clear clinical value and a direct line to recurring reimbursement, it often signals a meaningful inflection point rather than a routine early-stage round.
I think this is a big deal because Vertigenius is not just adding another app to the digital health pile; it is wiring a previously under-digitized specialty, vestibular rehab, into the emerging infrastructure of remote monitoring revenue and AI-assisted workflows. For a roughly $3 million raise, the strategic leverage is high: FDA clearance, an identified US reimbursement pathway and a focused clinical use case that payers can understand.
Sources
